Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 282

1.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

PMID:
28322237
2.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

3.

Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia.

Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK.

Leukemia. 2017 May;31(5):1234-1237. doi: 10.1038/leu.2017.37. Epub 2017 Jan 23. No abstract available.

PMID:
28111469
4.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

5.

The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities.

Chilton L, Hills RK, Burnett AK, Harrison CJ.

Leukemia. 2016 Nov;30(11):2264-2267. doi: 10.1038/leu.2016.200. Epub 2016 Jul 25. No abstract available.

6.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD.

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

7.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016.

8.

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE.

Leukemia. 2017 Feb;31(2):310-317. doi: 10.1038/leu.2016.225. Epub 2016 Sep 2.

9.

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.

Burnett AK, Russell NH, Hills RK; United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group.

Blood. 2016 Jul 21;128(3):449-52. doi: 10.1182/blood-2016-04-712091. Epub 2016 Jun 6. No abstract available.

10.

The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.

Dickson GJ, Bustraan S, Hills RK, Ali A, Goldstone AH, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2016 Feb;172(4):573-80. doi: 10.1111/bjh.13873. Epub 2015 Dec 21.

11.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group.

N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.

12.

Cord Blood-Derived Quiescent CD34+ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34+ Cells.

Munje C, Hills RK, Whetton A, Burnett AK, Darley RL, Tonks A.

Gene Expr. 2015;16(4):169-175. doi: 10.3727/105221615X14399878166159.

13.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group.

Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.

PMID:
26384238
14.

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.

Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, Tinsley S, Dickson G, Burnett AK, Hills RK, Linch DC.

J Clin Oncol. 2015 Jun 20;33(18):2072-83. doi: 10.1200/JCO.2014.59.2022. Epub 2015 May 11.

PMID:
25964253
15.

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

Lazenby M, Hills R, Burnett AK, Zabkiewicz J.

Leuk Res. 2015 Jun;39(6):617-24. doi: 10.1016/j.leukres.2015.03.016. Epub 2015 Mar 30.

16.

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK, Hills RK.

Br J Haematol. 2015 Jul;170(1):80-4. doi: 10.1111/bjh.13398. Epub 2015 Apr 14.

PMID:
25876768
17.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group.

Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1.

18.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

19.

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.

Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.

20.

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.

Coles SJ, Gilmour MN, Reid R, Knapper S, Burnett AK, Man S, Tonks A, Darley RL.

Leukemia. 2015 Sep;29(9):1952-4. doi: 10.1038/leu.2015.62. Epub 2015 Mar 9. No abstract available.

PMID:
25748687

Supplemental Content

Loading ...
Support Center